Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

AC Immune (ACIU) EBIT Margin: 2015-2025

Historic EBIT Margin for AC Immune (ACIU) over the last 10 years, with Sep 2025 value amounting to -1,721.62%.

  • AC Immune's EBIT Margin fell 175014.00% to -1,721.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,678.03%, marking a year-over-year decrease of 153630.00%. This contributed to the annual value of -191.80% for FY2024, which is 17050.00% up from last year.
  • As of Q3 2025, AC Immune's EBIT Margin stood at -1,721.62%, which was down 15.97% from -1,484.53% recorded in Q2 2025.
  • AC Immune's EBIT Margin's 5-year high stood at 34,935.00% during Q2 2024, with a 5-year trough of -507,075.00% in Q3 2021.
  • Over the past 3 years, AC Immune's median EBIT Margin value was -1,637.47% (recorded in 2024), while the average stood at 1,774.12%.
  • In the last 5 years, AC Immune's EBIT Margin plummeted by 50,540,047bps in 2021 and then spiked by 50,672,979bps in 2022.
  • Over the past 5 years, AC Immune's EBIT Margin (Quarterly) stood at -30,382.67% in 2021, then surged by 2,562,516bps to -4,757.51% in 2022, then spiked by 368,448bps to -1,073.03% in 2023, then tumbled by 56,444bps to -1,637.47% in 2024, then tumbled by 175,014bps to -1,721.62% in 2025.
  • Its EBIT Margin stands at -1,721.62% for Q3 2025, versus -1,484.53% for Q2 2025 and -1,956.57% for Q1 2025.